Phaseline

Companies › Sound Pharmaceuticals

Sound Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ebselen (SPI-1005)
Glutathione peroxidase mimetic
GPX1, GPX2, GPX3, GPX4Phase 3Meniere's Disease; Hearing LossDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06859788Ebselen (SPI-1005)Phase 3Meniere's DiseaseOtherDec 2026
NCT06340633Ebselen (SPI-1005)Phase 2Hearing LossOtherDec 2026

From the company's SEC filings

Cash of 655m CNY on 2025-12-31; operating cash flow positive

Targets

GPX1 (1) GPX2 (1) GPX3 (1) GPX4 (1)

Companies with the same targets

–

Companies built like this

Intuitive Surgical Palvella Therapeutics Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.